ArticleAlimentary pharmacology & therapeutics2026

Comparative Risk of Hepatitis B Virus Reactivation in Patients Receiving Immune Checkpoint Inhibitors or Tyrosine Kinase Inhibitors for Liver Cancer.

Dorothy Cheuk-Yan Yiu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.